血清LncRNA MEG3、SNHG5水平与慢性阻塞性肺疾病全球倡议分级及预后的相关性分析

石赟; 陈艳蓉; 张净; 罗佳

doi:10.7619/jcmp.20211770

血清LncRNA MEG3、SNHG5水平与慢性阻塞性肺疾病全球倡议分级及预后的相关性分析

Analysis of correlations between serum LncRNA MEG3, SNHG5 levels and global initiative classification for chronic obstructive lung diseases as well as prognosis

摘要

摘要:
目的分析血清长链非编码RNA母系表达基因3（LncRNA MEG3）、小核仁RNA宿主基因5（SNHG5）与慢性阻塞性肺疾病（COPD）患者COPD全球倡议（GOLD）分级及预后的关系。
方法将87例COPD急性加重期（AECOPD）患者纳入急性组，将急性组患者治疗1个月后病情恢复稳定的46例患者纳入稳定组，同期50例健康志愿者纳入对照组。分别检测急性组、稳定组和对照组血清LncRNA MEG3、SNHG5水平，并评估血清LncRNA MEG3、SNHG5水平与COPD患者GOLD分级、临床相关指标及预后的关系。
结果急性组及稳定组患者血清LncRNA MEG3、SNHG5水平均低于对照组，差异有统计学意义（P < 0.05）；急性组血清LncRNA MEG3、SNHG5水平低于稳定组，差异有统计学意义（P < 0.05）。急性组GOLD分级与稳定组比较，差异有统计学意义（P < 0.05）；急性组COPD多维分级评分系统（BODE）指数得分高于稳定组，差异有统计学意义（P < 0.05）。随访3个月，87例AECOPD患者共18例死亡，被纳入预后不良组，其余69例患者纳入预后良好组。预后不良组血清LncRNA MEG3、SNHG5水平低于预后良好组，差异有统计学意义（P < 0.05）。相关性分析提示，COPD患者血清LncRNA MEG3与吸烟史、GOLD分级、BODE指数呈负相关（P < 0.05），与第1秒用力呼气容积与用力肺活量的比值（FEV₁/FVC）呈正相关（P < 0.05）。LncRNA SNHG5水平与吸烟史、住院时间、GOLD分级及BODE指数呈负相关（P < 0.05），与FEV₁/FVC呈正相关（P < 0.05）。
结论 COPD患者血清LncRNA MEG3、SNHG5水平较健康者下降，且与患者肺功能及病情严重程度有关，对AECOPD患者短期死亡风险判断具有一定价值。

Abstract:
Objective To analyze the correlations of serum long non-coding RNA maternally expressed gene 3 (LncRNA MEG3) and small nucleolar RNA host gene 5 (SNHG5) with global initiative for chronic obstructive lung diseases (GOLD) classification and prognosis of chronic obstructive pulmonary disease (COPD) patients.
Methods A total of 87 patients with acute exacerbation of COPD (AECOPD) were selected as acute group, 46 patients in the acute group whose condition were stable after 1 month of treatment were included in stable group, and 50 healthy individuals were enrolled as control group. Serum LncRNA MEG3 and SNHG5 levels were detected in all three groups, then the correlations of serum LncRNA MEG3 and SNHG5 levels with GOLD classification, clinical indicators and prognosis of COPD patients were evaluated.
Results Serum LncRNA MEG3 and SNHG5 levels in the acute group and the stable group were lower than those in the control group (P < 0.05), and were lower in the acute group than those in the stable group (P < 0.05). GOLD grade showed significant difference between the acute group and the stable group, and the scores of body mass, airflow obstruction, dyspnea, and exercise capacity (BODE) index were significantly higher in the acute group than those in the stable group (P < 0.05). During 3 months of follow-up, 18 of 87 patients with AECOPD died and were included in poor prognosis group, and the remaining 69 patients were included in good prognosis group. The levels of serum LncRNA MEG3 and SNHG5 in the poor prognosis group were lower than those in the good prognosis group, and the differences were statistically significant (P < 0.05). Correlation analysis suggested that serum LncRNA MEG3 in COPD patients was negatively correlated with smoking history, GOLD grade and BODE index (P < 0.05), and positively correlated with ratio of forced expiratory volume to forced vital capacity in the first second (FEV₁/FVC) level (P < 0.05). The level of LncRNA SNHG5 was negatively correlated with smoking history, hospital stay length, GOLD grade and BODE index (P < 0.05), and positively correlated with FEV₁/FVC (P < 0.05).
Conclusion Serum LncRNA MEG3 and SNHG5 levels are significantly down-regulated in patients with COPD, and their levels show significant correlations with the pulmonary function and disease severity. Moreover, the two indicators are of great value in predicting the short-term death in AECOPD patients.

HTML全文

参考文献(15)

施引文献

资源附件(0)